Clinical evaluation of diphenylpyraline as an antifungal agent.

Abstract

CARSON and Campbell 1 reported that ``diphenylpyraline'' (1-methyl-piperidyl-4 benzhydryl ether) had marked in vitro antifungal action against a group of organisms, including Trichophyton rubrum, Microsporum gypseum, Microsporum lanosum, Epidermophyton floccosum, and Candida albicans. These authors enthusiastically suggested that clinical corroboration should be attempted. In response to this suggestion, a therapeutic trial was carried out. Except for the use of microscopic and culture technics, such as the use of a standard Sabouraud agar culture medium, to check clinical diagnosis, the study was entirely clinical. The chemical, pharmacologic, and physiologic aspects of ``diphenylpyraline'' will not be discussed at this time. Studies of these aspects have been accomplished elsewhere, and the results are to be published. The mode of administration of ``diphenylpyraline'' 2 was limited to topical application. The active agent was incorporated in two separate vehicles, the selection of which was guided by the physical state of the eruption. In wet, oozing,